Similar findings demonstrated significant evidence that PD-L1 was frequently expressed on metastatic cells circulating in the blood of HR(+) and HER2(−) breast cancer patients, whereas other studies have suggested that higher levels of CTLA-4 may be linked to more advanced stages of breast cancer, highlighting the significance of CTLA-4 in the growth and progress of the disease [24,35]. This evidence concerns the gene ERBB2 and breast carcinoma.